Monoclonal antibodies for targeted therapy in colorectal cancer

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Traditional cancer therapies like chemotherapy and radiotherapy lack specificity, causing significant side effects by damaging normal tissues.
• Monoclonal antibodies (mAbs) represent a targeted approach, binding to cancer-specific antigens and inhibiting overexpressed target proteins.
• mAbs have shown promise, particularly in patients resistant to conventional chemotherapy, for both solid tumors and hematological malignancies.

Purpose of the Study:

• To review current knowledge on monoclonal antibodies targeting growth factors in colorectal cancer.
• To highlight the importance of patient screening for optimizing therapeutic efficacy.

Main Methods:

• Review of existing literature on monoclonal antibodies in colorectal cancer treatment.
• Analysis of FDA-approved antibodies and their mechanisms of action.
• Discussion of patient selection strategies based on molecular targets.

Main Results:

• Monoclonal antibodies targeting growth factors are effective in treating metastatic colorectal cancer.
• Examples include FDA-approved agents like cetuximab, panitumumab, and bevacizumab.
• These targeted therapies can be effective in patients refractory to traditional chemotherapy.

Conclusions:

• Monoclonal antibodies targeting growth factors are a valuable therapeutic option for colorectal cancer.
• Careful patient screening is essential to identify individuals most likely to benefit from these targeted therapies.
• Further research into mAb mechanisms and patient selection will refine their clinical application.